SCHEMBL3434265

SCHEMBL3434265

Cc1ccc(N2CCN(CC(N)=O)CC2)c(N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 3/20 0.49
TSHR P16473 2/20 0.47
HTT P42858 1/20 0.47
PRMT1 Q99873 1/20 0.46
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
POLB P06746 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 4/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
DRD3 P35462 2/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3435654 0.89 ALDH1A1 (0.50) KDM4EALDH1A1TSHRHTTHSP90AA1
SCHEMBL3436303 0.87 HTT (0.53) KDM4EALDH1A1TSHRHTTPOLB
SCHEMBL3436302 0.84 TSHR (0.66) ALDH1A1TSHRHTTPOLBMEN1
SCHEMBL2080162 0.83 ALDH1A1 (0.50) KDM4EALDH1A1HSD17B10HTTPRMT1
SCHEMBL2079365 0.83 POLB (0.57) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL3435091 0.83 ALDH1A1 (0.57) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL3435121 0.82 USP8 (0.47) KDM4EALDH1A1HSD17B10TSHRPRMT1
SCHEMBL3435114 0.81 ALDH1A1 (0.46) KDM4EALDH1A1HSD17B10PRMT1HSP90AA1
SCHEMBL10278255 0.80 MAPT (0.60) KDM4EALDH1A1TSHRHTTPRMT1
SCHEMBL3436164 0.80 LMNA (0.54) KDM4EALDH1A1HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 KDM4E 1834/4885ALDH1A1 975/4885HSD17B10 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.